Le Lézard
Classified in: Health
Subject: FDA

PolyPid Announces Receipt of Qualified Infectious Disease Product (QIDP) Designation from FDA for D-PLEXtm in Post-Cardiac Surgery Sternal Infection


PETAH TIKVA, Israel, March 8, 2017 /PRNewswire/ -- PolyPid Ltd., an emerging clinical-stage specialty pharmaceutical company focused primarily on the development of a post-surgical anti-infective pipeline, announced today that the Company's lead product candidate, D-PLEXtm (Doxycycline/Polymer-Lipid Encapsulation Matrix), a secured antibiotic drug reservoir that provides a safe and effective local anti-bacterial prevention and treatment measure during surgical procedures, has been designated as a Qualified Infectious Disease Product (QIDP) by the U.S. Food & Drug Administration (FDA).

Under the FDA's QIDP program, which is designed to speed the development of novel drugs against important pathogens, PolyPid will be able to take advantage of certain incentives, including FDA priority review, eligibility for fast-track status and an additional five-years of market exclusivity when marketing approval is granted for D-PLEXtm in preventing post-cardiac surgery sternal infection.

Post-cardiac surgery sternal infection is an unmet medical need and one of the most significant complications following open cardiac surgery, which according to known literature carries has a mortality rate reaching 40%.  

"The receipt of QIDP designation from the FDA represents an important milestone that expedites and extends the commercial path for D-PLEXtm in the U.S.," said Amir Weisberg, PolyPid's Chief Executive Officer.  "We view this QIDP designation as validation of the significant potential of D-PLEXtm in preventing and treating surgical site infections.  We look forward to the availability of additional data by year-end 2017 from our ongoing Phase Ib/II study in Israel of D-PLEXtm in post-cardiac surgery sternal infection." 

Initial data from the ongoing Phase Ib/II study of D-PLEXtm in Israel showed no sternal infection occurred during three-month follow-up in the treated patients. Moreover, D-PLEXtm was safe and there were no adverse events related to the product.

PolyPid intends to seek regulatory approvals in the U.S. and Europe in the coming year to conduct a Phase III trial of D-PLEXtm in post-cardiac surgery sternal infection.  The Company recently completed a successful pre-Investigational New Drug Application meeting with the FDA in which the Agency agreed that D-PLEXtm can move directly into a Phase III trial in the U.S., based on the phase Ib/II satisfactory results.  In addition, the FDA agreed that D-PLEXtm would be reviewed under the 505(b)(2) approval pathway.

About D-PLEXtm

PolyPid's lead product, D-PLEXtm, is a secure antibiotic drug reservoir that provides a safe and effective local anti-bacterial preventive and treatment at the target site and is designed to be administered during surgical procedures. After surgery, the drug reservoir constantly releases the entrapped antibiotic over several weeks, thus allowing prolonged infection management with increased potential to eradicate antibiotic resistant bacteria.

About PolyPid

PolyPid is a clinical stage, emerging specialty pharmaceutical company, developing, manufacturing and commercializing products based on a proprietary platform, PLEXtm (Polymer-Lipid Encapsulation matriX), in the field of extended release, local drug delivery. PLEXtm technology optimizes drug therapeutic performance and clinical outcomes, improves pharmacoeconomic potential and offers lifecycle extension for novel drugs. This is achieved via protected drug reservoirs enabling prolonged delivery of drugs, including biologics, over periods ranging from days to several months. The application of PLEXtm technology enables optimized drug treatment regimens by predetermining release rates and durations, a rare combination of attributes. PLEXtm-based products have demonstrated an excellent safety profile during extended clinical studies, with over 65 patients exposed to the technology to date.  PolyPid's technology and products are based on the inventions of Dr. Noam Emanuel, the founder and the chief technology officer of the company.

For additional company information, visit www.polypid.com.

Company contact:


PolyPid, Ltd. 
Dikla Czaczkes Akselbrad
Chief Financial Officer
+972-74-7195753
[email protected]
www.polypid.com

LifeSci Advisors
Bob Yedid
Managing Director
+646-597-6989
[email protected]

SOURCE PolyPid Ltd.


These press releases may also interest you

at 06:50
Merck , known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then...

at 06:31
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual...

at 06:30
Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular...

at 06:30
The collagen water market is booming thanks to the growing popularity of health and beauty products. Consumers are more interested in skincare and healthy eating, which is driving manufacturers to create collagen-infused drinks and cosmetics. A new...

at 06:30
Viavi Solutions Inc. (VIAVI)  today announced it has participated in the 2024 RIC Forum, March 26-28, in Dallas, Texas. The company contributed its TeraVM RIC Test and TM500 Network Tester to multiple demonstrations, building on collaborations at MWC...

at 06:30
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points  New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively...



News published on and distributed by: